10 September 2024 The upcoming European Society for Medical Oncology (ESMO) Congress 2024 should provide a reminder—if it were needed—of the pace of innovation in the development of new medicines for cancer.
Even as emerging signs of a thaw in the broader Indian start-up funding landscape were evident, the Competition Commission of India (CCI) has tightened its exemption list under new combination rules. 11 September 2024
Eli Lilly has announced positive results from two Phase III trials evaluating its once-weekly insulin efsitora alfa (efsitora) against the daily insulin degludec for adults with type 1 and type 2 diabetes. 11 September 2024
Viridian Therapeutics has reported positive topline data from its Phase III THRIVE clinical trial of veligrotug, an intravenous treatment for thyroid eye disease (TED). 11 September 2024
MAIA Biotechnology yesterday announced favorable interim survival benefit from its lead clinical candidate THIO, a telomere-targeting treatment for patients with advanced 11 September 2024
New obesity drugs from public and private companies are emerging to challenge the leading positions of Denmark-based Novo Nordisk and US pharma major Eli Lilly in a GLP-1 drug market that is estimated to reach more than $200 billion in annual sales by 2031. 11 September 2024
The upcoming European Society for Medical Oncology (ESMO) Congress 2024 should provide a reminder—if it were needed—of the pace of innovation in the development of new medicines for cancer. 10 September 2024
Swiss pharma giant Roche today announced the opening of the new pharmaceutical research and development center at its global headquarters in Basel. 10 September 2024
Roivant today announced its previously undisclosed pipeline program mosliciguat, a potential first-in-class, inhaled, once-daily sGC activator with targeted delivery to the lungs via dry powder inhaler, at Pulmovant. 10 September 2024
Californian companies Gilead Sciences and Genesis Therapeutics have entered into a strategic collaboration to discover and develop novel, small molecule therapies across multiple targets. 10 September 2024
Several pharma companies that had moved the Delhi High Court against the government’s recent notification banning 156 fixed-dose combination (FDC) drugs have got a breather. 10 September 2024
The US House of Representatives has passed the BIOSECURE Act, gaining bipartisan support with a vote of 306–81. Nearly all of the votes against the bill came from Democrats. 10 September 2024
Detailed results were released from the TROPION-Lung01 Phase III trial, which showed a clinically meaningful trend toward improving overall survival (OS) with datopotamab deruxtecan (Dato-DXd) compared to docetaxe. 10 September 2024
Candid Therapeutics, a San Diego biotech focused on developing potentially transformative drugs to address autoimmune diseases, has announced its official launch. 10 September 2024
French cancer focused biotech Transgene has appointed two seasoned leaders in oncology who will be instrumental in advancing the company’s innovative immunotherapy programs 10 September 2024
Boehringer Ingelheim has reported positive results from a Phase Ib primary analysis of Cohort 1 of the Beamion LUNG-1 trial evaluating zongertinib (BI 1810631) in pre-treated patients with advanced non-small cell lung cancer (NSCLC) with activating HER2 mutations. 10 September 2024
Superluminal Medicines, a US firm using generative biology, chemistry and machine learning in an attempt to revolutionize the speed and accuracy of how medicines are created, has closed a $120 million Series A funding round. 10 September 2024
Even as emerging signs of a thaw in the broader Indian start-up funding landscape were evident, the Competition Commission of India (CCI) has tightened its exemption list under new combination rules. 11 September 2024
Eli Lilly has announced positive results from two Phase III trials evaluating its once-weekly insulin efsitora alfa (efsitora) against the daily insulin degludec for adults with type 1 and type 2 diabetes. 11 September 2024
Viridian Therapeutics has reported positive topline data from its Phase III THRIVE clinical trial of veligrotug, an intravenous treatment for thyroid eye disease (TED). 11 September 2024
MAIA Biotechnology yesterday announced favorable interim survival benefit from its lead clinical candidate THIO, a telomere-targeting treatment for patients with advanced 11 September 2024
New obesity drugs from public and private companies are emerging to challenge the leading positions of Denmark-based Novo Nordisk and US pharma major Eli Lilly in a GLP-1 drug market that is estimated to reach more than $200 billion in annual sales by 2031. 11 September 2024
The upcoming European Society for Medical Oncology (ESMO) Congress 2024 should provide a reminder—if it were needed—of the pace of innovation in the development of new medicines for cancer. 10 September 2024
Swiss pharma giant Roche today announced the opening of the new pharmaceutical research and development center at its global headquarters in Basel. 10 September 2024
Roivant today announced its previously undisclosed pipeline program mosliciguat, a potential first-in-class, inhaled, once-daily sGC activator with targeted delivery to the lungs via dry powder inhaler, at Pulmovant. 10 September 2024
Californian companies Gilead Sciences and Genesis Therapeutics have entered into a strategic collaboration to discover and develop novel, small molecule therapies across multiple targets. 10 September 2024
Several pharma companies that had moved the Delhi High Court against the government’s recent notification banning 156 fixed-dose combination (FDC) drugs have got a breather. 10 September 2024
The US House of Representatives has passed the BIOSECURE Act, gaining bipartisan support with a vote of 306–81. Nearly all of the votes against the bill came from Democrats. 10 September 2024
Detailed results were released from the TROPION-Lung01 Phase III trial, which showed a clinically meaningful trend toward improving overall survival (OS) with datopotamab deruxtecan (Dato-DXd) compared to docetaxe. 10 September 2024
Candid Therapeutics, a San Diego biotech focused on developing potentially transformative drugs to address autoimmune diseases, has announced its official launch. 10 September 2024
French cancer focused biotech Transgene has appointed two seasoned leaders in oncology who will be instrumental in advancing the company’s innovative immunotherapy programs 10 September 2024
Boehringer Ingelheim has reported positive results from a Phase Ib primary analysis of Cohort 1 of the Beamion LUNG-1 trial evaluating zongertinib (BI 1810631) in pre-treated patients with advanced non-small cell lung cancer (NSCLC) with activating HER2 mutations. 10 September 2024
Superluminal Medicines, a US firm using generative biology, chemistry and machine learning in an attempt to revolutionize the speed and accuracy of how medicines are created, has closed a $120 million Series A funding round. 10 September 2024
Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news
Company Spotlight
A clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body.